Arecor fully funded and gearing up to take flagship diabetes drug into clinic

Sarah Howell, chief executive of Arecor, tells Proactive London's Andrew Scott they have a dual business model - there's a technology business where they partner with major pharmaceutical companies, taking their products in-house, apply their technology to deliver back to them an improved product profile and she says that's been very successful .. profitable in its own right and with the upside potential of royalties.

The other side of the business is focused on developing their own portfolio of drugs, initially focused on the diabetes therapeutic area.

''We know that from working with major pharma that we can deliver products that they are unable to develop themselves ... so there is room for a company like Arecor''.

''Ultimately for some of these products for major markets such as insulin we'll look to partner for late stage commercialisation ... so yes we're competing with them but we also see them as partners moving forward''.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...


Hikma Pharmaceuticals and Arecor strike a second strategic partnership deal

Arecor Limited's Sarah Howell talks to Proactive London about the announcement to expand their agreement with Hikma Pharmaceuticals PLC (LON:HKMA) to co-develop ready-to-administer injectable medicines in the US to a second product. As Howell explains, this deal follows on from the first...

on 10/20/2020

2 min read